Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The use of chemotherapy in patients with acute myeloid leukemia (AML) is associated with survival benefits and alleviation of symptoms related to AML. Prior studies have demonstrated a lower receipt of chemotherapy with increasing age and comorbidities. We hypothesized that socioeconomic and health system factors also determine the use of chemotherapy. We included 61 775 adults with AML diagnosed between 2003 and 2011 from the National Cancer Database, and performed a multivariable logistic regression model to determine the association between receipt of chemotherapy and several factors. A total of 15 608 patients (25.3%) did not receive chemotherapy. In a multivariable analysis, the likelihood of getting chemotherapy declined with increasing age and comorbidities and among patients with therapy-related and intermediate-/high-risk AML. Other factors associated with a lower likelihood of receiving chemotherapy included receipt of care in nonacademic centers, African American race, lower income status, uninsured or Medicare insurance status, and female sex. Compared with the previous studies, our study is novel because it provides data from a large, unselected cohort of patients diagnosed in the United States in recent years, and simultaneously examines the effect of various biological, socioeconomic, and health system factors. The results of our study raise a possibility of leukemia care disparity based on socioeconomic and health system factors. Better understanding of ways such factors may influence receipt of chemotherapy may allow an increase in the use of chemotherapy.

Original languageEnglish (US)
Pages (from-to)1277-1282
Number of pages6
JournalBlood Advances
Volume2
Issue number11
DOIs
StatePublished - Jun 12 2018

Fingerprint

Acute Myeloid Leukemia
Drug Therapy
Comorbidity
Health
Logistic Models
Insurance Coverage
Medicare
African Americans
Leukemia
Databases
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States. / Bhatt, Vijaya R; Shostrom, Valerie; Gundabolu, Krishna; Armitage, James Olen.

In: Blood Advances, Vol. 2, No. 11, 12.06.2018, p. 1277-1282.

Research output: Contribution to journalArticle

@article{9726a54f67c745f7af561da471acb699,
title = "Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States",
abstract = "The use of chemotherapy in patients with acute myeloid leukemia (AML) is associated with survival benefits and alleviation of symptoms related to AML. Prior studies have demonstrated a lower receipt of chemotherapy with increasing age and comorbidities. We hypothesized that socioeconomic and health system factors also determine the use of chemotherapy. We included 61 775 adults with AML diagnosed between 2003 and 2011 from the National Cancer Database, and performed a multivariable logistic regression model to determine the association between receipt of chemotherapy and several factors. A total of 15 608 patients (25.3{\%}) did not receive chemotherapy. In a multivariable analysis, the likelihood of getting chemotherapy declined with increasing age and comorbidities and among patients with therapy-related and intermediate-/high-risk AML. Other factors associated with a lower likelihood of receiving chemotherapy included receipt of care in nonacademic centers, African American race, lower income status, uninsured or Medicare insurance status, and female sex. Compared with the previous studies, our study is novel because it provides data from a large, unselected cohort of patients diagnosed in the United States in recent years, and simultaneously examines the effect of various biological, socioeconomic, and health system factors. The results of our study raise a possibility of leukemia care disparity based on socioeconomic and health system factors. Better understanding of ways such factors may influence receipt of chemotherapy may allow an increase in the use of chemotherapy.",
author = "Bhatt, {Vijaya R} and Valerie Shostrom and Krishna Gundabolu and Armitage, {James Olen}",
year = "2018",
month = "6",
day = "12",
doi = "10.1182/bloodadvances.2018019125",
language = "English (US)",
volume = "2",
pages = "1277--1282",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States

AU - Bhatt, Vijaya R

AU - Shostrom, Valerie

AU - Gundabolu, Krishna

AU - Armitage, James Olen

PY - 2018/6/12

Y1 - 2018/6/12

N2 - The use of chemotherapy in patients with acute myeloid leukemia (AML) is associated with survival benefits and alleviation of symptoms related to AML. Prior studies have demonstrated a lower receipt of chemotherapy with increasing age and comorbidities. We hypothesized that socioeconomic and health system factors also determine the use of chemotherapy. We included 61 775 adults with AML diagnosed between 2003 and 2011 from the National Cancer Database, and performed a multivariable logistic regression model to determine the association between receipt of chemotherapy and several factors. A total of 15 608 patients (25.3%) did not receive chemotherapy. In a multivariable analysis, the likelihood of getting chemotherapy declined with increasing age and comorbidities and among patients with therapy-related and intermediate-/high-risk AML. Other factors associated with a lower likelihood of receiving chemotherapy included receipt of care in nonacademic centers, African American race, lower income status, uninsured or Medicare insurance status, and female sex. Compared with the previous studies, our study is novel because it provides data from a large, unselected cohort of patients diagnosed in the United States in recent years, and simultaneously examines the effect of various biological, socioeconomic, and health system factors. The results of our study raise a possibility of leukemia care disparity based on socioeconomic and health system factors. Better understanding of ways such factors may influence receipt of chemotherapy may allow an increase in the use of chemotherapy.

AB - The use of chemotherapy in patients with acute myeloid leukemia (AML) is associated with survival benefits and alleviation of symptoms related to AML. Prior studies have demonstrated a lower receipt of chemotherapy with increasing age and comorbidities. We hypothesized that socioeconomic and health system factors also determine the use of chemotherapy. We included 61 775 adults with AML diagnosed between 2003 and 2011 from the National Cancer Database, and performed a multivariable logistic regression model to determine the association between receipt of chemotherapy and several factors. A total of 15 608 patients (25.3%) did not receive chemotherapy. In a multivariable analysis, the likelihood of getting chemotherapy declined with increasing age and comorbidities and among patients with therapy-related and intermediate-/high-risk AML. Other factors associated with a lower likelihood of receiving chemotherapy included receipt of care in nonacademic centers, African American race, lower income status, uninsured or Medicare insurance status, and female sex. Compared with the previous studies, our study is novel because it provides data from a large, unselected cohort of patients diagnosed in the United States in recent years, and simultaneously examines the effect of various biological, socioeconomic, and health system factors. The results of our study raise a possibility of leukemia care disparity based on socioeconomic and health system factors. Better understanding of ways such factors may influence receipt of chemotherapy may allow an increase in the use of chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85057235844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057235844&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018019125

DO - 10.1182/bloodadvances.2018019125

M3 - Article

VL - 2

SP - 1277

EP - 1282

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 11

ER -